Expand all sections

Sugemalimab

Extended indication Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma.
Therapeutic value No estimate possible yet
Total cost 24,575,000.00
Registration phase Clinical trials

Product

Active substance Sugemalimab
Domain Oncology
Reason of inclusion Indication extension
Main indication Oncology other
Extended indication Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma.
Manufacturer CStone
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2024
Expected Registration 2025
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Pdl-1 remmers.
Therapeutic value No estimate possible yet
Substantiation Er zijn nog geen resultaten bekend.
Frequency of administration 1 times every 3 weeks
Dosage per administration 1200mg
References NCT04187352

Expected patient volume per year

Patient volume

447 - 536

Market share is generally not included unless otherwise stated.
References NKR2021; Epidemiology of Esophageal Squamous Cell Carcinoma. Christian C. Abnet.;
Additional remarks In 2021 zijn in Nederland 1.787 patiënten met stadium III en IV slokdarmkanker gediagnosticeerd. In ongeveer 25 tot 30% van de gevallen zal het een plaveisel carcinoom betreffen.

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
Additional remarks Afhankelijk van de studieresultaten wordt er verwacht dat de kosten van deze behandeling in lijn liggen met andere PD-L1 remmers

Potential total cost per year

Total cost

24,575,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.